Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-Radiochemotherapy and Pembrolizumab vs Pembrolizumab in Recurrent HNSCC
NCT07026474Phase 3Recruiting
- Sponsor
- Saarland University
- Start
- Oct 2025
- Primary completion
- Dec 2032
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Saarland University. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07026474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07026474.